Screening, interventions and collaborative care models for increasing SUD treatment in primary care.

Opioid and other substance related deaths continue to rise in the U.S. (CDC, May 2022). A treatment model that includes professionals working across disciplines and settings, especially primary care – which is the most common point of healthcare contact – could help address the opioid and substance use crisis by increasing access to evidence based screening and interventions. The National Institute on Drug Abuse (NIDA) Drug Treatment Clinical Trials Network (CTN) has conducted several trials in these settings and this session will provide insights from investigators on successful models for substance and opioid use disorders (SUD/OUD) screening, prevention, and treatment in primary care.

This session will provide an overview and rationale of establishing primary care models for screening and interventions for SUD, and the main objectives are to learn about (1) approaches for incorporating alcohol and drug screening into primary care practices, integrated with the electronic health record (EHR); (2) lessons learned from SUD collaborative care trials in primary care settings; and (3) establishing collaborative care models in Federally Qualified Health Centers (FQHC), including pharmacists, in SUD/OUD treatment and management.

Presentation Slides:

• CTN and the expansion of SUD treatment delivery in primary care settings – C. Rosa, M.S.
• Primary care provider role in SUD screening, prevention, and treatment – G. Bart, M.D.
• Feasibility of implementing alcohol and drug screening in primary care – J. McNeely, MD, MS
• Lessons learned and unanswered questions from trials of collaborative care for alcohol and substance use disorders – K. Bradley, M.D.
• Pharmacist-Integrated Collaborative Care in OUD Treatment – L. Marsch, PhD